1. Home
  2. In The News
  3. HHS Spurs Development of Smallpox Therapeutic to Enhance Health Security

HHS Spurs Development of Smallpox Therapeutic to Enhance Health Security

From U.S. Department of Health and Human Services
By DHHS 26SEP2019

The U.S. Department of Health and Human Services will sponsor development of a novel therapeutic to treat smallpox infections. The variola virus, which causes smallpox was eradicated but remains a potential health security threat…

Read Full Article

September 26, 2019 In The News
About BioFactura

BioFactura (Frederick MD) develops and commercializes high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast Biomanufacturing Platform, the optimal system for bringing these drugs to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases.